Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Фаза 2
Завершено
NCT02296684
| Заболевание | Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Washington University School of Medicine |
|---|
| Статус | Завершено |
|---|
| Участники | 67 участн. |
|---|
| Вмешательство | MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy, Image-guided radiation therapy, Cisplatin |
|---|
| Дата начала | 25.03.2015 |
|---|
| Дата завершения | 5.04.2022 |
|---|
| Публикация результатов | 11.05.2023 |
|---|
Кратко
The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.
Locoregional Recurrence Rates in Cohorts 1 and 2
Within 1 year of surgery (surgery occurred within 13-22 days after neoadjuvant MK-3475 dose) · Participants
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 2 Participants |
|---|
| Cohort 2: Neoadjuvant MK-3475 | 2 Participants |
|---|
Distant Failure Rate in Cohorts 1 and 2
Within 1 year of surgery (surgery occurred within 13-22 days after neoadjuvant MK-3475 dose) · Participants
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 3 Participants |
|---|
| Cohort 2: Neoadjuvant MK-3475 | 1 Participants |
|---|
Rate of Major Pathologic Treatment Effect in Cohort 1
At the time of surgery (surgery occurred within 13-22 days after neoadjuvant MK-3475 dose) · Participants
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 20 Participants |
|---|
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 8 Participants |
|---|
| Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475 | 8 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.